Financial & Investment
Biotech funding when venture capital turns selective: routes for CEOs
Venture dollars have recovered but are concentrated in later-stage companies. Plan partnership, royalty and non-dilutive capital alongside equity, not after it. The report sets out the considerations and practical implications discussed in the article.
- Format
- PDF · 15 pages
- Published
- Published Oct 2026
- Article
- Read the article
What's inside
- 01Venture dollars recovered in 2025, but flowed to fewer, later companies
- 02Capital is available across the industry, but venture is a minority
- 03The IPO window is reopening selectively, which rewards preparation
- 04Partnership capital, including from China, is now a core financing route
- 05Royalty and structured finance have moved from niche to mainstream